BioSpace News Archive

89bio, Inc. announced that the Company’s Management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 7th Annual NASH Investor Conference being held on Tuesday, October 24, 2023.

NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”) today presented a poster with interim Phase I trial data on the use of its investigational NK cell therapy, SNK01, to treat patients with Alzheimer’s disease (“AD”) at the XXVI World Congress of Neurology (WCN) Annual Meeting in Montreal, QC, Canada and online.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company, today announced results of a pre-clinical study on its CRB-913 cannabinoid type-1 receptor (CB1) inverse agonist have been selected for oral presentation at the 11th annual Obesity Journal Symposium, held during the 2023 Obesity Week Conference in Dallas, Texas October 14-17, 2023.

ImmunoForge today announced that it has dosed the first patient in its Phase 2 clinical trial to evaluate the efficacy, safety, and pharmacokinetic properties of Froniglutide in patients with dermatomyositis/polymyositis.

Seelos Therapeutics, Inc. announced that it has retained Canaccord Genuity to assist in its ongoing review of potential partnerships, collaborations, and similar opportunities.

Thermo Fisher Scientific Inc. and Olink Holding AB announced that their respective boards of directors have approved Thermo Fisher’s proposal to acquire Olink for $26.00 per common share in cash, representing $26.00 per American Depositary Share in cash.

NeuroSense Therapeutics Ltd., a company developing treatments for severe neurodegenerative diseases, provided an update from its CEO, Alon Ben-Noon, on the Company’s clinical and operational developments during and immediately following the third quarter of 2023.

Single-cell and spatially resolved omics have helped scientists take a closer look at tissue composition, structure, and function.

CARGO Therapeutics, Inc. (CARGO), a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the appointment of Ginna Laport, MD, as Chief Medical Officer.

Jiangsu Hengrui Pharmaceuticals Co., Ltd. and Elevar Therapeutics, Inc. announced a global licensing agreement that grants Elevar rights to commercialize and develop Hengrui Pharma’s anti-PD-1 antibody camrelizumab in combination with rivoceranib for unresectable hepatocellular carcinoma worldwide, excluding Greater China Region and Korea.